1-(4-羟基-3-碘-5-甲氧基苯基)乙酮 | 103440-59-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(4-羟基-3-碘-5-甲氧基苯基)乙酮
• 英文名称: ethanone-1-[3-methoxy-4-hydroxy-5-iodophenyl]
• 英文别名: 1-[3-methoxy-4-hydroxy-5-iodophenyl]ethanone；5-iodoacetovanillone；1-(4-hydroxy-3-iodo-5-methoxy-phenyl)ethan-1-one；4'-hydroxy-3'-iodo-5'-methoxyacetophenone；1-(3-iodo-4-hydroxy-5-methoxy-phenyl)-ethanone；1-(4-hydroxy-3-iodo-5-methoxy-phenyl)-ethanone；1-(4-Hydroxy-3-jod-5-methoxy-phenyl)-aethanon；1-(4-Hydroxy-3-iodo-5-methoxyphenyl)ethanone
• CAS: 103440-59-1
• 化学式: C₉H₉IO₃
• 分子量: 292.073
• InChiKey: JSZQVDXPKCAQJM-UHFFFAOYSA-N

物化性质

• 熔点：
  179°C
• 沸点：
  341.8±42.0 °C(Predicted)
• 密度：
  1.765±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(4-羟基-3-碘-5-甲氧基苯基)乙酮 在 盐酸 、 sodium methylate 、 potassium carbonate 作用下， 以 四氢呋喃 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 20.5h， 生成 1-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-iodophenyl]prop-2-en-1-one
  参考文献：
  名称：

  (±)-Trans-2-[3-methoxy-4-(4-chlorophenyl thioethoxy)-5-cyanophenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran, a potent PAF-receptor antagonist

  摘要：

  The synthesis of (+/-)-trans-2-[3-methoxy-4-(chlorophenylthioethoxyphenyl)-5-cyanophenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran from conmercially available acetovanillone and 3,4,5-trimethoxybenzaldehyde is described. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(99)00544-x
• 作为产物：
  描述：

  香草乙酮 在 碘 、 碳酸氢钠 、 potassium iodide 作用下， 生成 1-(4-羟基-3-碘-5-甲氧基苯基)乙酮
  参考文献：
  名称：

  AN IMPROVED SYNTHESIS OF ACETOSYRINGONE

  摘要：

  乙酰丁香酚已经从乙酰香草酮合成，产率超过50％，通过将其转化为5-碘乙酰香草酮，然后在铜催化剂存在下与甲酸钠发生反应。先前未报道的中间体5-碘乙酰香草酮通过甲基化为5-碘乙酰香草酮，随后氧化为已知的5-碘香酸。

  DOI：

  10.1139/v56-204

文献信息

• Substituted benzyl pyrimidines
  申请人：Hoffmann-La Roche Inc.

  公开号：US05763450A1

  公开（公告）日：1998-06-09

  Compounds of the formula: ##STR1## in which R.sup.1 is lower alkoxy, R.sup.2 is bromine or lower alkoxy, and R.sup.3 is aryl, heteroaryl or a group --Q--R.sup.30, wherein Q is ethylene, vinylene or ethynylene and R.sup.30 is aryl, heteroaryl, lower alkoxycarbonyl or carbamoyl; hydrolyzable esters of carboxylic acids of formula I; and pharmaceutically acceptable salts of these compounds are useful for treating infectious diseases.

  公式为：##STR1## 其中 R.sup.1 是较低的烷氧基，R.sup.2 是溴或较低的烷氧基，R.sup.3 是芳基、杂环芳基或一个基团--Q--R.sup.30，其中 Q 是乙烯基、乙烯基或乙炔基，R.sup.30 是芳基、杂环芳基、较低的烷氧基羰基或氨基甲酰基；公式 I 的羧酸的可水解酯；以及这些化合物的药用可接受的盐，适用于治疗传染病。
• AN IMPROVED SYNTHESIS OF ACETOSYRINGONE
  作者：L. W. Crawford、E. O. Eaton、J. M. Pepper

  DOI：10.1139/v56-204

  日期：1956.11.1

  Acetosyringone has been synthesized from acetovanillone, in better than a 50% yield, through conversion to 5-iodoacetovanillone followed by its interaction with sodium methoxide in the presence of copper catalyst. The previously unreported intermediate, 5-iodoacetovanillone, was characterized by methylation to 5-iodoacetoveratrone and subsequent oxidation to the known 5-iodoveratric acid.

  乙酰丁香酚已经从乙酰香草酮合成，产率超过50％，通过将其转化为5-碘乙酰香草酮，然后在铜催化剂存在下与甲酸钠发生反应。先前未报道的中间体5-碘乙酰香草酮通过甲基化为5-碘乙酰香草酮，随后氧化为已知的5-碘香酸。
• PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS
  申请人：——

  公开号：US20030008914A1

  公开（公告）日：2003-01-09

  A pharmaceutical formulation is provided for the treatment of inflammatory and/or immune disorders, particularly those mediated by platelet activating factor (“PAF”) or a product of 5-lipoxygenase. The formulation, in one embodiment, is an essentially anhydrous ointment containing an active agent selected from the group consisting of 2,5-diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 2,4-diaryl tetrahydrofurans, 2,4-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes, 2,4-diaryl pyrrolidines, and 2,5-diaryl pyrrolidines, and an enhancer composition containing one or more C 3-18 esters such as diethyl succinate, propylene carbonate, diisopropyl adipate and glyceryl triacetate. In another embodiment, the formulation is a cream, gel, lotion, oil, or the like, containing the: active agent in crystalline form. The invention also encompasses the novel crystalline form of the active agent, and methods for using the formulations to treat individuals with inflammatory and/or immune disorders. Also encompassed is use of isopropyl alcohol (IPA) to enhance stability of the active agent and pharmaceutical formulations.

  提供了一种用于治疗炎症和/或免疫紊乱的制药配方，特别是那些由血小板活化因子（“PAF”）或5-脂氧合酶产物介导的疾病。在一个实施例中，该配方是一种基本无水的软膏，含有从2,5-二芳基四氢呋喃、2,5-二芳基四氢噻吩、2,4-二芳基四氢呋喃、2,4-二芳基四氢噻吩、1,3-二芳基环戊烷、2,4-二芳基吡咯烷和2,5-二芳基吡咯烷等化合物组成的活性剂，以及一个增效剂组合，其中包含一个或多个C3-18酯，如琥珀酸二乙酯、碳酸丙二酯、己二酸二异丙酯和三乙酰甘油。在另一个实施例中，该配方是一种乳霜、凝胶、乳液、油剂等，含有晶体形式的活性剂。该发明还涵盖了该活性剂的新晶体形式，以及使用这些配方治疗患有炎症和/或免疫紊乱的个体的方法。还包括异丙醇（IPA）用于增强活性剂和制药配方的稳定性。
• COMPOUND, RESIN, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：US20210389669A1

  公开（公告）日：2021-12-16

  Disclosed are a compound represented by formula (I), a resin and a resist composition: wherein R 1 represents an alkyl group having 1 to 6 carbon atoms which may have a halogen, hydrogen or halogen atom, R 2 and R 3 each independently represent a hydrogen atom or a hydrocarbon group having 1 to 12 carbon atoms, R 4 represents a fluorine atom, an alkyl fluoride group having 1 to 6 carbon atoms or an alkyl group having 1 to 12 carbon atoms, and —CH 2 — included in the alkyl fluoride group and the alkyl group may be replaced by —O— or —CO—, R 5 represents a hydrogen atom, an alkylcarbonyl group having 2 to 6 carbon atoms or an acid-labile group, m2 represents an integer of 1 to 4, m4 represents an integer of 0 to 3, and m5 represents 1 or 2, in which 2≤m2+m4+m5≤5.

  揭示了一种由公式（I）表示的化合物，树脂和抗蚀组合物： 其中R1代表具有1至6个碳原子的烷基基团，其可以具有卤素，氢或卤素原子，R2和R3各自独立地表示氢原子或具有1至12个碳原子的碳氢基团，R4表示氟原子，具有1至6个碳原子的烷基氟化物基团或具有1至12个碳原子的烷基基团，且包括在烷基氟化物基团和烷基基团中的-CH2-可以被- O-或-CO-所取代，R5表示氢原子，具有2至6个碳原子的烷基羰基基团或酸敏感基团，m2表示1至4的整数，m4表示0至3的整数，m5表示1或2，在其中2≤m2+m4+m5≤5。
• Method for synthesizing diaryl-substituted heterocyclic compounds, including tetrahydrofurans
  申请人：——

  公开号：US20020128491A1

  公开（公告）日：2002-09-12

  A method is provided for synthesizing diaryl-substituted heterocyclic compounds, particularly 2,5-diaryl-substituted tetrahydrofurans and tetrahydrothiophenes. Methods for synthesizing starting materials and intermediates are provided as well. An important application of the invention is in the synthesis of CMI-392, (±) trans-2-[5-(N′-methyl-N′-hydroxyureidyl-methyl)-3-methoxy-4-p-chlorophenylthioethoxyphenyl]-5-(3,4,5-trimethoxyphenyl)-tetrahydrofuran, a highly effective agent in treating inflammatory and immune disorders. The invention also encompasses novel compounds useful as starting materials and intermediates in the synthetic processes disclosed.

  本发明提供了一种合成二芳基取代杂环化合物的方法，特别是2,5-二芳基取代四氢呋喃和四氢噻吩的方法。同时还提供了合成起始材料和中间体的方法。本发明的一个重要应用是在合成CMI-392中，(±)反-2-[5-(N'-甲基-N'-羟基脲基甲基)-3-甲氧基-4-p-氯苯硫醚基苯基]-5-[3,4,5-三甲氧基苯基]-四氢呋喃，这是一种在治疗炎症和免疫性疾病方面非常有效的药物。本发明还包括作为合成过程中起始材料和中间体的新化合物。